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Chronic Myelogenous Leukemia: Molecule to Man

Robert Peter Gale, MD, PhD'

Chronic myelogenous leukemia (CML) is lhe best understood human cancer. The molecular basis of
CML involves activation ofa cellular proto-oncogene—ABL. The consequence is to increase tyrosine
kinase aciivity. This results in a marked clonal increase in the myeloid mass. Later on. cellular
maturation is blocked and the decrease eventuates in acute leukemia. Abnormalities of olher protooncogenes or antioncogenes. like P53, may he involved in leukemia progression. Trealment of CML
involves chemotherapy and, more recently, interferon. Whether this trealment prolongs survival or
increases lhe likelihood tfcure is unknown hul eilher result seems unlikely. Bone marrow transplants
which cure about 50% of persons with CML are mosl effective when performed in chronic phase.
(Henn Ford Hosp MedJ 1991:39:108-11 j

C

hronic myelogenous leukemia (CML) is a malignancy of
myeloid cells and their progenitors. C M L is divided into
two phases, a chronic phase in which the myeloid mass is markedly increased but cell maturation appears normal, and an acute
phase with impaired maturation. This latter phase resembles
acute leukemia. This review considers four aspects of CML: cell
biology, molecular biology, treatment, and bone marrow transplantation.

Cell Biology
The characteristic feature of C M L is a marked increase in
myeloid cells and their progenitors. The underiying pathophysiology is not understood. Some data suggest a slight maturational
defect in C M L cells which results in the occurrence of several
additional cell divisions before cells enter the nonproliferative,
nonmitotic pool. The hierarchical structure of hematopoiesis
amplifies this modest abnormality resulting in production of
substantially more end cells which correspond to the clinical
phenotype of CML. For example, it is estimated that each progenitor cell may produce as many as 10'' end cells. This would
involve about 17 cell divisions. A small increase in proliferation
of these myeloid progenitor cells, by three or four divisions,
would increase granulocytes tenfold to sixteenfold.
C M L is a clonal disorder. The Philadelphia (Ph) chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22, is found in granulocyte progenitors, macrophages, RBC progenitors, megakaryocytes, and some B lymphocytes (1-4). However, it is not typically found in T-cells or
their progenitors (5-10). These data suggest that transformation
occurs within a progenitor cell to myelopoiesis and B-cell (but
not T-cell) development. T-cells are sometimes involved in the
C M L clone. In such an instance a less mature progenitor cell is
probably transformed. Data regarding sites of transformation
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have been confirmed by molecular studies of the BCR and A B L
genes [vide infra) and by studies of polymorphic genetic systems on the X chromosome.
The clonal increase in myelopoiesis typical of C M L is accompanied by decreased normal polyclonal hematopoiesis. The
reason for this decrease is uncertain. One possibility is that regulatory mechanisms operate effectively to suppress proliferation
by normal (but not CML) progenitor cells. It is also possible that
cells of the C M L clone release factors that suppress normal hematopoiesis. Cytogenetic analyses of bone marrow from per.sons with C M L often show only cells derived from the C M L
clone. However, considerable data show that normal stem cells
persist; normal metaphases can be detected under a variety of
circumstances. These include the following: overdoses of busulfan, intensive chemotherapy, treatment with interferon, and in
vitro bone marrow culture. Furthermore, normal metaphases
have been observed in persons with C M L receiving autotransplants ( I I ) .
A third aspect of the cell biology of C M L is the inevitable
progression to acute phase. When this occurs, cell maturation
that characterizes the chronic phase is lost. Myeloid cells remain
within the proliferative pool. Progression to acute phase occurs
at a rate of approximately 10% in the first year following diagnosis and approximately 25% per year thereafter. By eight
years, less than 20% of persons with C M L remain in chronic
phase. Several mechanisms might explain progression to acute
phase. One possibility is that the duration of chronic phase is genetically predetermined. It is also possible that progression is a
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F'lg I—Evolution of chronic myelogenous leukemia. N = normal hematopoiesis; X = clonal hematopoiesis; Ph = Ph-positive
clone; Ph' = Ph clone with additional changes, a; An event occurs in a hematopoietic stem cell leading to proliferation of that
clone X, while normal hematopoiesis N is suppressed, h; The
t(9;22) occurs in the X clone leading to CML, the WBC increases, and clinical features ofthe disease develop while normal hematopoiesis is further suppressed, c: The diagnosis is
made and the disease treated, clinical features resolve with partial recovery of normal hematopoiesis N. d; The disease is controlled with chemotherapy for a median period of 3'/2 years;
eventually it becomes more difficult to control. Accelerated
phase is indicated hy the fagged line, e; Additional abnormalities occur in the Ph clone leading to acute phase disease Ph'
with an increasing WBC and loss of maturation ofthe cells; normal clones N are again suppressed, as is the Ph clone, f; The
disease bectmies uncontrollable, leading to death. The issue of
whether clonal hematopoiesis precedes the Ph chromosome is
controversial. (From Gale RP. Chronic myelogenous leukaemia; A model for human cancers. Balliere's Clinical Hematology 1987;1 ;869-86. Reprinted with permission.)

stochastic event correlated with the numbers of myeloid progenitor cells or stem ceUs. The likelihood of progression to acute
phase may be correlated with the proliferative state of myeloid
progenitor cells. Some data suggest that the t(9;22) translocation may not be the initial event in CML (12,13). B-cell lines derived from persons with CML show a skewed distribufion of Xchromosome linked polymorphic alleles suggesting evolution
from the CML clone. However, these cells lack the t(9;22)
translocation. These data lead to a scheme of CML shown in Fig
1 (14). Here, an initial lesion may lead to clonal expansion ofa
myeloid progenitor. This event is probably without clinical consequence. Later, the t(9;22) translocation may impart a proliferative advantage to this clone resulting in a clinical phenotype of
CML. This phase of CML is best regarded as a preleukemia
since differentiation appears normal. The next phase of CML
occurs when additional genetic changes result in loss of maturational capacity of cells and is best regarded as acute leukemia. In
contrast to chronic phase CML, where the myeloid mass can be
controlled by chemotherapy or interferon, the acute phase is resistant to treatment.
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Fig 2—Schematic representation of the BCR and ABL genes
showing known econs (indicated as boxes); introns are shown
as lines. The arable numbers below the BCR gene Identify the
exons within the breakpoint cluster region (2). Representative
positions for the breakpoints In CML and Ph-positive ALL are
shown as vertical dashed lines. The breakpoint in m-BCR gives
rise to the fused gene Ph + ALL (helow), and the two different
breakpoints in M-BCR give rise to the two genes with slightly different linkages characteristic of CML. (From Gale RP,
Goldman JM. Rapid progress in chronic myelogenous leukemia. Leukemia 1988;2;321-4. Reprinted with permission.)

Molecular Biology
Investigations in our laboratory as well as in others have determined the molecular basis of CML (15,16) (Fig 2). The 3'
portion of the ABL proto-oncogene is translocated into the 5'
portion of the BCR gene. In CML, breakpoints in BCR occur
within a specific region of the BCR gene designated M-BCR.
Within this region, breakpoints occur either between the second
and third or third and fourth exons. Breaks within the ABL gene
typically occur between the two alternative first exons designated 1^ and Ij,. The chimeric BCR-ABL gene is transcribed to
an 8.3 kilobase (kb) chimeric mRNA and translated to a chimeric 210 kilodalton (kd) protein. This protein, unlike the normal
145 kd ABL gene product, has prominent tyrosine kinase activity. This increased kinase activity is thought to result from the
amino terminal modification ofthe normal ABL protein and resembles activation of ABL by gag sequences in acutely transforming retroviruses. The substrate of the 210 kd BCR/ABL
protein is unknown but it is capable of autophosphorelation.
Transformation of rat embryo fibroblasts has been observed following infecfion with a retrovirus containing a DNA construct
of the rearranged human BCR/ABL gene. Recently, infecfion of
murine bone marrow with this construct was shown to cause a
disease resembling CML. These data suggest that the rearranged
BCR-ABL gene causes CML. Whether its introduction results
in chronic and acute phase or chronic phase only is unknown.
A different rearrangement of BCR and ABL is found in about
one-half of cases of Ph'-chromosome posifive acute leukemias,
predominantiy acute lymphoblastic leukemia (ALL). In ALL,
only the first exon of BCR is linked to the same exons of ABL.
This results in a chimeric gene transcribed into a 7.0 kb chimeric
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mRNA and translated into a 190 kd chimeric protein, also with
increased tyrosine kinase activity. The other half of cases of Phchromosome ALL have the 210 kd type of rearrangement. Some
data suggest that younger persons may be more likely to have
the 190 kd type rearrangement but this is uncertain.
The molecular basis of transition to acute phase is less certain.
There is no evidence that further rearrangement within the BCRABL chimeric gene coincides with transition to acute phase.
Some recent reports indicate rearrangement of the P53 antioncogene in acute phase CML while others found no rearrangement.
The P53 antioncogene maps to chromosome 17p, a region involved in isochromosome 17 rearrangement which is associated
with acute phase. The emerging of isochromosome 17 results in
loss of one allele of P53; rearrangement or mutation of the remaining allele may inactivate P53. Since isochromosome 17 occurs in only about 15% to 20% of persons with acute phase
CML, other mechanisms are likely to be involved in transition
to acute phase in most cases. Other cytogenetic abnormalities
typical of acute phase of CML are reviewed elsewhere (17).
Based on these data we suggest that these additional cytogenetic
abnormalities may determine the phenotype of acute phase.

Therapy
Since transition to acute phase results in death within one
year, duration of chronic phase is the major determinant of survival in CML. There are two possible objectives of CML therapy: increasing the duration of chronic phase, and increasing
likelihood of cure. These objectives differ. Increasing duration
of chronic phase would result in increased survival but need not
be accompanied by increased cures. In contrast, cure requires
preventing transition to acute phase.
Drugs used to treat CML include busulfan, hydroxyurea,
cytarabine, anthracyclines, purines, and others (16,18). Busulfan and hydroxyurea control myeloid mass in chronic phase but
have no effect on duration nor do they reduce the likelihood of
transition to acute phase. Multidrug chemotherapy is no more
effective than single drugs. Recently interferon has been shown
to control myeloid mass in chronic phase CML. Interferon treatment reduces the portion of Ph'-chromosome positive cells detected in the bone marrow. However, it is unknown whether this
effect correlates with a reduced number of myeloid progenitor
cells at risk for transformation to acute phase. Furthermore,
there are no convincing data that the duration of chronic phase
or the likelihood of transition to acute phase is affected by interferon therapy.

Transplants
Several types of bone marrow transplants are performed in
persons with CML including those from human lymphocyte
antibody (HLA)-identical related donors (typically siblings),
transplants from HLA-matched unrelated donors, and autotransplants. Data from the Intemational Bone Marrow Transplantation Registry in about 1,200 persons with CML receiving
HLA-idenfical transplants indicate five-year disease-free survival of about 45% in chronic phase, 30% in accelerated phase,
and 20% in acute phase (19). Results are best in young persons.
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in those receiving posttransplant immune suppression with cyclosporine and methotrexate, in those not receiving T-cell depleted transplants, in persons with chronic but not acute graftversus-host disease (GvHD), and in those in whom transplants
were performed within one year of diagnosis (20). Outcomes of
transplants in different phases of disease reflect predominantly
different risks of leukemia recurrence: about 20% in chronic
phase and about 60% in more advanced CML.
Detailed analysis of relapse rates in persons with CML in
chronic phase receiving bone marrow transplants under diverse
circumstances suggests that the major means of leukemia eradication is probably an immune mechanism. Recipients of HLAidentical transplants who develop chronic GvHD have a substantially lower risk of leukemia relapse than those without it
(21). Also, recipients of T-cell depleted transplants have a markedly increased risk of leukemia relapse (22). There is a similarly
high relapse rate in persons receiving transplants from genetically identical twins (23). Analysis of these data suggests that
for CML in chronic phase the major means of leukemia eradication are chronic GvHD and a T-cell effect of GvHD. Genetic differences between donor and recipient may also be beneficial in
view ofthe high relap.se rate in twins. Probably several mechanisms operate.
The notion that leukemia eradication is not a direct result of
high doses of chemotherapy and radiation is confirmed by analyses of bone marrow cells from persons with CML who receive
transplants. Sensitive techniques, including the polymerase
chain reaction, can detect cells with the BCR-ABL gene rearrangement up to five years posttransplant; most ofthese persons
have not yet developed clinical evidence of recurrent CML (2426). These data suggest that immune or other regulatory mechanisms controlled residual CML cells during the time these subjects were observed.
Most subjects with CML lack a HLA-identical sibling or a
twin donor. Recently, these persons have received transplants
from nonsibling HLA-identical or matched related or unrelated
donors (27-29). Results are slightiy inferior to those observed
using perfectly matched donors. However, in view of the incurability of CML by other approaches, transplantation from a suitably matched unrelated donor seems reasonable.
Autotransplants have also been reported in CML (30). These
are performed in acute or chronic phase using blood- or bone
marrow-derived progenitor cells. Sometimes the bone marrow
has been treated in vitro to decrease or eliminate Ph-chromosome positive cells. Techniques to remove CML cells from the
bone marrow to be reinfused include short-term bone marrow
culture, interferon, and anti-leukemia drugs such as hydroperoxycyclophosphamide. In some instances, the subject has received chemotherapy or interferon prior to bone marrow procurement resulting in a decrease in Ph'-chromosome positive
cells in the harvested bone marrow. Encouraging preliminary
results have been reported with several of these approaches. The
high relapse rates in persons without GvHD after receiving allogeneic transplants for CML in chronic phase and in recipients of
transplants from twins suggest that eradication of leukemia in
the recipient is a major obstacle to success of autotransplants.
None of the techniques reported to eliminate CML cells in vitro
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has been studied in randomized trials; consequently, their efficacy is unknown. Although transplants in acute phase typically
restore chronic phase, its duration is invariably brief. Most data
suggest that the acute phase recurs from cells persisting in the
recipient rather than in the graft. Results of autotransplants in
chronic phase indicate that a small proportion of subjects become partially Ph'-chromosome negative for a brief period; a
few are Ph'-chromosome negative for two or three years.

Summary
Substantial progress has been made in our understanding and
treatment of CML. The molecular basis of CML is clear, but the
preci.se mechanism by which the chimeric BCR-ABL tyrosine
kinase results in an expansion of the myeloid mass in chronic
phase is unknown. The molecular basis of the acute phase of
CML is less well studied but the P53 antioncogene may play a
role in some ca.ses.
Progress in treating CML is less rapid. Interferon therapy decreases the proportion of Ph' chromosome positive cells in the
blood and bone marrow. Whether it affects CML progenitor
cells is unknown. Consequently, its effect on prolonging duration of chronic phase or reducing the likelihood of transition to
acute phase is unproved. Bone marrow transplantation, particularly from a HLA-identical sibling, results in about 50% fiveyear disea.se-free survival when performed in chronic phase. Results are less impressive in more advanced CML but are clearly
better than any alternative. Despite some interesting outcomes
following autotransplants. it is unlikely that this approach can
cure CML. The efficacy of transplants in CML relates more to
immunological or regulatory factors affecting hematopoiesis
than to high-dose chemotherapy and/or radiation. These data
may provide interesting insights into future control and/or treatment of CML.
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